Literature DB >> 12635901

Statistical issues on objective, design, and analysis of noninferiority active-controlled clinical trial.

Yi Tsong1, Sue Jane Wang, H M James Hung, Lu Cui.   

Abstract

In practice, "noninferiority" active-controlled trials have been designed for three different objectives: establishing evidence of efficacy over placebo, preserving a specific percentage of the effect size of the active control, or demonstrating the test treatment is "not much inferior" to the active control. All three objectives can be represented by the same set of statistical hypotheses with the parameters defined differently. The various designs and statistical analysis procedures for active-controlled trials proposed in the literature can be group into two basic types: the historical-controlled trial approach and the cross-study comparison approach. These approaches require some unverifiable constancy assumptions. Under the constancy assumptions, the cross-study comparison uses the estimate effect of active-control treatment as the unbiased estimate of the active/placebo difference in the current noninferiority trial. A normalized Z-statistic is used to test the hypotheses. On the other hand, the historical controlled trial approach uses a conservative confidence limit as if it were a constant to replace the active/placebo difference in the current trial. The two approaches may lead to consistent conclusions only when the constancy assumptions can be supported by a large number of historical studies giving a consistent active-control treatment effect over placebo and that the active-control effect does not change over time.

Mesh:

Substances:

Year:  2003        PMID: 12635901     DOI: 10.1081/BIP-120017724

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

Review 1.  Rationale for and methods of superiority, noninferiority, or equivalence designs in orthopaedic, controlled trials.

Authors:  Patrick Vavken
Journal:  Clin Orthop Relat Res       Date:  2011-01-19       Impact factor: 4.176

2.  Creative trial design in RA: optimizing patient outcomes.

Authors:  Maya H Buch; Sue Pavitt; Mahesh Parmar; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2013-02-05       Impact factor: 20.543

3.  Non-inferiority test for a continuous variable with a flexible margin in an active controlled trial: an application to the "Stratall ANRS 12110 / ESTHER" trial.

Authors:  Arsene Brunelle Sandie; Nicolas Molinari; Anthony Wanjoya; Charles Kouanfack; Christian Laurent; Jules Brice Tchatchueng-Mbougua
Journal:  Trials       Date:  2022-03-05       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.